Pfizer (PFE) Payables (2009 - 2026)

Pfizer (PFE) has reported Payables for 18 consecutive years, with $7.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 7.61% year-over-year to $7.0 billion in Q2 2026; TTM through Jun 2026 was $7.0 billion, a 7.61% decrease from a year earlier, with the FY2025 full-year figure at $7.7 billion, down 4.77% from the prior year.
• Payables was $7.0 billion for Q2 2026 at Pfizer, up from $4.5 billion in the prior quarter.
• Over five years, Payables peaked at $9.1 billion in Q4 2022 and troughed at $4.5 billion in Q1 2026.
• A 5-year average of $6.9 billion and a median of $7.3 billion in 2024 frame the typical range for Payables.
• Across the five-year window, Payables soared 35.48% in 2022 and decreased 14.01% in 2026, its largest moves.
• Over 5 years, Payables stood at $9.1 billion in 2022, then declined by 0.33% to $9.1 billion in 2023, then dropped by 11.14% to $8.1 billion in 2024, then declined by 4.77% to $7.7 billion in 2025, then slipped by 8.5% to $7.0 billion in 2026.
• The last three Payables figures came in at $7.0 billion (Q2 2026), $4.5 billion (Q1 2026), and $7.7 billion (Q4 2025), per Business Quant data.